Engaging an experienced partner to oversee the work of outsourced preclinical development is an effective strategy for smaller biopharma companies who typically operate with lean internal teams. While capital efficiency is important, the quality and integrity of preclinical programs cannot be compromised. We offer an efficient model for early-stage companies to leverage specialized knowledge and guidance in a variable way, keeping fixed costs down while advancing preclinical development with sound planning, input and oversight.
Download our fact sheet to learn more.